A Pilot Study to Evaluate the Effects of Perfusion-decellularized Porcine Hepatic-derived Wound Matrix on Difficult-to-heal Diabetic Foot Ulcers

Fridman, R. A.; Engelhardt, Jonathan

doi:10.25270/wnds/2017.10.317323

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among six patients, three patients showed complete wound closure by 56 ± 21 days, that is 42.9%, two patients showed partial closure, by 28.6%, and one patient had a worse wound, that is 14.3%. [55] Cytal is an acellular, non-crosslinked, and lyophilized porcine urinary bladder (UBM) wound matrix with an epithelial basement membrane containing collagens type IV and VII and a porous lamina propria that allows host cell infiltration. Post implantation, host macrophage, and neutrophils enter the UBM matrix and initiate the remodeling process.…”

Section: Scaffolds Derived From Xenogeneic Sourcesmentioning

confidence: 99%

See 1 more Smart Citation

Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products

Sharma

Zhao

2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Impaired wound healing after trauma, disorders, and surgeries impact millions of people globally every year. Dysregulation in orchestrated healing mechanisms and underlying medical complications make chronic wound management extremely challenging. Besides standard‐of‐care treatments including broad spectrum antibiotics and wound‐debridement, novel adjuvant therapies are clinically tested and commercialized. These include topical agents, skin substitutes, growth factor delivery, and stem cell therapies. With a goal to overcome factors playing pivotal role in delayed wound healing, researchers are exploring novel approaches to elicit desirable healing outcomes in chronic wounds. Although recent innovations in wound care products, therapies, and devices are extensively reviewed in past, a comprehensive review summarizing their clinical outcomes is surprisingly lacking. Herein, this work reviews the commercially available wound care products and their performance in clinical trials to provide a statistically comprehensive understanding of their safety and efficacy. The performance and suitability of various commercial wound care platforms, including xenogeneic and allogenic products, wound care devices, and novel biomaterials, are discussed for chronic wounds. The current clinical evaluation will provide a comprehensive understanding of the benefits and drawbacks of the most‐recent approaches and will enable researchers and healthcare providers to develop next‐generation technologies for chronic wound management.

show abstract

Section: Scaffolds Derived From Xenogeneic Sourcesmentioning

confidence: 99%

Section: Commercial Products For Chronic Wounds Treatmentmentioning

confidence: 99%

Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products

Sharma

Zhao

2023

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Diabetic foot ulcer(DFU) is a rather common comorbidity of diabetes [ 2 ]. The lifetime risk of developing DFU for diabetics is up to 25% [ 3 ]. Among old adults, more presence of senescent cells has been hypothesized to contribute to pathophysiological conditions, which is the main factor for higher DFU morbidity [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Harnessing strategies for enhancing diabetic wound healing from the perspective of spatial inflammation patterns

Cai

Chen

Liu

et al. 2023

Bioactive Materials

View full text Add to dashboard Cite

Extracellular Matrix-Derived Hydrogels to Augment Dermal Wound Healing: A Systematic Review

Vriend

Sinkunas

Camargo

et al. 2022

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

Chronic, non-healing, dermal wounds form a worldwide medical problem with limited and inadequate treatment options and high societal burden and costs. With the advent of regenerative therapies exploiting extracellular matrix (ECM) components, its efficacy to augment wound healing is to be explored. This systematic review was performed to assess and compare the current therapeutic efficacy of ECM hydrogels on dermal wound healing. The electronic databases of Embase, Medline Ovid, and Cochrane Central were searched for in vivo and clinical studies on the therapeutic effect of ECM-composed hydrogels on dermal wound healing (April 13, 2021). Two reviewers selected studies independently. Studies were assessed based on ECM content, ECM hydrogel composition, additives, and wound healing outcomes, such as wound size, angiogenesis, and complications. Of the 2102 publications, 9 rodent-based studies were included while clinical studies were not published at the time of the search. Procedures to decellularize tissue or cultured cells and subsequently generate hydrogels were highly variable and in demand of standardization. ECM hydrogels with or without additives reduced wound size and also seem to enhance angiogenesis. Serious complications were not reported. To date, preclinical studies preclude to draw firm conclusions on the efficacy and working mechanism of ECM-derived hydrogels on dermal wound healing. The use of ECM hydrogels can be considered safe. Standardization of decellularization protocols and implementation of quality and cytotoxicity controls will enable obtaining a generic and comparable ECM product.

show abstract

A Pilot Study to Evaluate the Effects of Perfusion-decellularized Porcine Hepatic-derived Wound Matrix on Difficult-to-heal Diabetic Foot Ulcers

Cited by 5 publications

References 0 publications

Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products

Updates on Recent Clinical Assessment of Commercial Chronic Wound Care Products

Harnessing strategies for enhancing diabetic wound healing from the perspective of spatial inflammation patterns

Extracellular Matrix-Derived Hydrogels to Augment Dermal Wound Healing: A Systematic Review

Contact Info

Product

Resources

About